Summary of Use during Lactation

No information is available on the clinical use of abrocitinib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during abrocitinib therapy and for 1 day after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Abrocitinib

CAS Registry Number

1622902-68-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Janus Kinase Inhibitors

JAK Inhibitors